RxDoctor Payments Data

Peter Landstrom, APRN

Psychiatric/Mental Health, Adult · Westfield, MANPI 1427138254

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $776 of the $949 with a category attached, or 81.8%. 10 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 25.8% of the total.

$949in general payments, 2019–2025

Across 53 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$244
  • Vanda Pharmaceuticals Inc.$192
  • E.r. Squibb & Sons, L.L.C.$163
  • Teva Pharmaceuticals USA, Inc.$122
  • Lundbeck LLC$51
  • Johnson & Johnson$48
  • plus $129 from 4 others

What the payments were for

  • Food & beverage$77682%
  • Education$17318%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$949 in reported general payments places this provider in the 75th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.

See all psychiatric/mental health, adult providers in Massachusetts

Medicare billing

Part B allowed, 2024
$65,928
Medicare patients
303
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate91$267,695
IngrezzaValbenazine Tosylate17$137,407
Risperidone ErRisperidone Microspheres88$131,320
Risperdal ConstaRisperidone Microspheres38$89,884
VraylarCariprazine Hcl36$46,631
Abilify MaintenaAripiprazole12$35,189
Clozapine537$29,830
Lurasidone Hcl73$29,265
Aripiprazole306$25,331
Quetiapine Fumarate390$8,878
Divalproex Sodium ErDivalproex Sodium256$8,660
Risperidone485$7,345
Olanzapine327$7,320
Haloperidol271$7,224
Paliperidone ErPaliperidone72$6,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$48$357,578129 claims
Neurocrine Biosciences, Inc.Ingrezza$22$137,40717 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$244$35,18912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.

Other psychiatric/mental health, adult in Westfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →